However, pRCC is a genetically distinct form of RCC driven by MET mutations and gains of chromosomes 7,12,16 and 17 as possible drivers [11, 12]; and in the present study, enrichment of VEGF pathway conversely suggests increased responsiveness of VEGFR tartgeted therapies among black patients with pRCC. This evidence concerns the gene VEGFA and renal cell carcinoma.